麦高证券重整进展不及预期；定增募资不及预期；资本市场行情大 幅波动的风险。 业绩简评 2025 年 8 月 27 日，公司披露 2025 年度中期业绩：公司 2025 年 上半年实现营收 9.3 亿元，同比增长 71.6%；净利润为 1.4 亿元， 较上年同期扭亏，其中麦高证券净利润上半年为 0.7 亿元，同比增 长 614.5%，以及报告期内公司收购先锋基金股权并进行并表，形 成了0.66亿元的投资收益。报告期内公司扣非后归母净利润为0.7 亿元，较上年同期转亏。 2024 年第二季度，公司营业收入为 3.9 亿元，同比增长 56.2%； 净利润为 332 万元，扣非后归母净利润为 283 万元，均较上年同 期扭亏。 经营分析 金融信息服务业务 2025 年上半年营收为 6.8 亿元，同比增长 60.4%；销售商品、提供劳务收到的现金为 7.2 亿元，同比增长 46.9%。主要由于 2025 年第一季度公司开展完成了高端产品全赢 系列私享家版的营销，且报告期内市场行情较好。上半年销售费用 中的职工薪酬支出/金融信息服务收入为 26.1%，较上年同期该比 值下滑 2.3pct。 麦高证券上半年营收为 3.2 ...

Report Summary 1) Report Industry Investment Rating No relevant content provided. 2) Core Viewpoints of the Report - If PPI is to turn positive by the end of this year, the average monthly PPI MoM from August to December needs to reach 0.43%, similar to the average during the 2016 supply - side reform. Commodity prices need to rise significantly, with rebar, anthracite, copper, and crude oil prices needing to increase by 11% from July levels [2][8]. - Given that crude oil and copper are globally - priced commodities and crude oil prices have been weakening, domestic - priced commodities like rebar and coal need to rise more for PPI to turn positive by the end of the year. For example, if oil and copper prices remain flat, rebar and anthracite need to rise about 20% from July averages [8]. - A more realistic scenario is for PPI to approach positive growth in Q2 next year. With a low - base effect, rebar, anthracite, copper, and crude oil prices only need to rise about 4% from July this year to drive PPI to turn positive [9]. - PPI turning positive depends on demand. Weak demand can block price transmission, requiring larger price increases in upstream commodities for PPI to turn positive [12]. 3) Summary by Related Catalog Current Commodity Price Situation - Since July, commodities first rose and then slightly declined. As of mid - August, coal and ferrous metals rose 13.8% and 3.9% MoM respectively compared to mid - July, leading the increase among major commodities [4]. - Due to a low base last year, the PPI YoY in August is expected to rebound but will still remain in negative territory for the 34th consecutive month [4]. PPI Composition and Impact Factors - In the PPI composition, the weights of ferrous metals, non - ferrous metals, crude oil, coal, and other commodities are 13.6%, 7.3%, 16.7%, 9.3%, and 53.2% respectively. From January to July 2025, crude oil, ferrous metals, coal, and other commodities dragged down PPI by 1, 0.9, 0.5, and 0.9 percentage points respectively, while non - ferrous metals boosted PPI by 0.4 percentage points [4]. Representative Commodities for PPI - The spot prices of rebar, anthracite, copper, and Brent crude oil are selected as representative commodities for ferrous, coal, non - ferrous, and crude oil PPI, with correlation coefficients of 81%, 93%, 75%, and 96% respectively [5]. Historical Examples of Commodity Price Increases - In 2021, "sports - style" energy conservation and emission reduction drove coal prices up. In October 2021, anthracite prices rose 198% compared to April, driving the PPI YoY of the coal mining and washing industry from 13% to 103.7% in October [8]. - From 2016 - 2017, the supply - side reform drove up ferrous metal prices. At the end of 2016, rebar and wire rod prices rose 82% and 91% compared to the end of 2015, driving the PPI YoY of the ferrous metal smelting and rolling processing industry up by 35% at the end of 2016 [9]. Commodity Price Requirements for PPI to Turn Positive | Time | Rebar | Anthracite | Copper | Crude Oil | Average Commodity Price Increase | | --- | --- | --- | --- | --- | --- | | July Average | 3213 yuan/ton | 844 yuan/ton | 78644 yuan/ton | 71 dollars/ton | - | | Q4 2025 | 3580 yuan/ton | 940 yuan/ton | 87609 yuan/ton | 79 dollars/ton | 11% | | Q1 2026 | 3519 yuan/ton | 924 yuan/ton | 86115 yuan/ton | 78 dollars/ton | 10% | | Q2 2026 | 3342 yuan/ton | 877 yuan/ton | 81789 yuan/ton | 74 dollars/ton | 4% | [10]

Investment Rating - The report suggests a strong investment outlook for the AI pharmaceutical industry, highlighting the imminent approval of the first AI-driven drug as a pivotal moment for investment opportunities [5]. Core Insights - The application of AI in drug development is transitioning from concept to reality, with multi-omics development expected to reduce costs and increase efficiency by 1000 times, marking the dawn of a new era in innovative drug development [12][16]. - The report emphasizes the importance of computational power, data quality, and model development as critical factors driving the success of AI in pharmaceuticals [3][48]. - Major technology companies are entering the AI pharmaceutical space, with significant investments from top pharmaceutical firms, indicating a robust shift in the industry landscape [4][5]. Summary by Sections AI Application and Industry Transformation - AI applications in pharmaceuticals are moving towards practical implementation, with significant milestones such as the success of AlphaFold in protein structure prediction [12]. - The report notes that the AI pharmaceutical sector is on the verge of a transformative phase, driven by advancements in multi-omics applications [16]. Computational Power and Data Utilization - The availability of cloud computing resources from major tech companies like Amazon and Google is enhancing the computational capabilities necessary for AI applications in drug development [3]. - Innovations in federated learning are breaking down data silos, allowing for better data sharing while maintaining privacy, which is crucial for AI model training [37][39]. Industry Dynamics and Major Players - The entry of tech giants like NVIDIA and Google into the AI pharmaceutical space is reshaping the industry, with substantial investments in AI drug development [4]. - Leading pharmaceutical companies are also heavily investing in AI-related initiatives, with over $50 billion in significant transactions occurring in the past five years [4]. Investment Strategies - The report recommends focusing on companies with rich pipelines and strong validation capabilities, such as Insilico Medicine and Crystal Holding, as they are poised to benefit from the upcoming breakthroughs in AI drug approvals [5]. - It also suggests monitoring traditional pharmaceutical companies that are making significant strides in AI, such as CSPC Pharmaceutical Group and Fosun Pharma, for potential high returns [5].

Group 1: Core Views - The report emphasizes that the global stock market has seen significant increases since the tariff conflicts in April, with A-shares showing strong performance due to improved manufacturing sentiment and rising expectations for interest rate cuts [4][12] - The report suggests that the A-share market's strength is driven by China's sensitivity to global manufacturing demand and diverse external markets, alongside supportive domestic policies [4][12] - The report indicates that the TMT and military sectors have outperformed, with valuation levels reaching historical highs, while the healthcare sector and ChiNext still show significant valuation dispersion [4][13] Group 2: Industry Recommendations - For the machinery sector, Xugong Machinery is recommended due to domestic demand stabilization and overseas market recovery, with short-term catalysts from specific projects [19] - In the non-ferrous metals sector, China Rare Earth is favored due to policy support and rising processing fees, indicating a potential third wave of price increases [20] - China Pacific Insurance is highlighted in the non-bank financial sector, benefiting from low valuations and expected profit growth due to a favorable shift in product offerings [21] - In the building materials sector, Keda Manufacturing is recommended for its strong market position and growth potential in African markets [22] - For transportation, Milkewei is noted for its integrated logistics and chemical distribution advantages, with growth expected in the hazardous materials logistics sector [23] - In defense and military, AVIC Chengfei is recognized as a leading manufacturer with strong growth prospects in military exports and technological innovation [24] - In the biopharmaceutical sector, Kelun-Bio is recommended for its leading position in ADC technology and strong pipeline prospects [25] - Tencent Holdings is highlighted in the media and internet sector for its AI integration and growth in advertising revenue [26] - In the electronics sector, Lante Optics is favored due to strong demand in automotive and smart imaging applications [28] - Hikvision is recommended in the computer sector for its recovery in operating quality and growth in AI-related products [30]

业绩简评 2025 年 8 月 27 日公司披露 25 年半年报，上半年公司实现营收 171.4 亿元，同比增长 45.3%；实现归母净利润 6.1 亿元，同比下 降 7.7%；其中，公司 Q2 实现营收 94.4 亿元，同比增长 40.4%， 环比增长 22.5%，实现归母净利润 3.1 亿元，同比下降 13.6%，环 比增长 1.9%。 经营分析 收入规模大幅增长，制造盈利预计小幅修复：上半年公司实现产 品销售收入 158 亿元，同比增长 51.2，毛利率约为 10.1%，同比 改善 0.20pct；其中风机及配件销售业务实现收入 124.8 亿元，同 比增长 57.5%，占比 79%，同比提升 3pct；电站产品销售业务收入 31.4 亿元，同比增长 48.6%，占比 20%，同比持平。考虑到上半年 产品销售收入中风机制造业务占比略有提升，以及在"136"号文 落地背景下电站产品销售毛利率大概率下降，我们预计风机及配 件销售业务毛利率存在小幅改善。展望后续，在风机价格企稳回升 的背景下，看好公司制造端毛利率持续回暖。 "两海"战略稳步推进，有望逐步贡献业绩弹性：海风方面，上半 年公司成功实现全球单体容量 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of 5% to 15% over the next 6 to 12 months [5][13]. Core Insights - The company reported a revenue of 14.875 billion yuan for the first half of 2025, representing a year-on-year growth of 39.3%, and a net profit attributable to shareholders of 2.693 billion yuan, up 42.9% year-on-year [2]. - Revenue exceeded expectations, with strong cost control leading to profits also surpassing forecasts. The sales from products and equipment reached 14.495 billion yuan and 0.38 billion yuan respectively, with year-on-year growth of 39.6% and 29.8% [3]. - The company accelerated its store openings, surpassing 53,000 global stores, with a net increase of 6,535 stores in the first half of 2025 [4]. - Domestic growth remains robust while international expansion is being optimized, particularly in Southeast Asia and Central Asia [4]. Financial Performance - The company has adjusted its profit forecasts upwards, expecting net profits of 5.953 billion yuan, 6.436 billion yuan, and 7.183 billion yuan for FY2025, FY2026, and FY2027 respectively, with corresponding P/E ratios of 27, 25, and 22 [5]. - Key financial metrics indicate a revenue growth rate of 49.55% for 2023, with a projected growth of 22.29% in 2024 [10].

业绩简评 2025 年 8 月 27 日，公司披露 2025 年半年报，上半年实现营收 108.9 亿元，同比增长 26.3%，实现归母净利润 1.44 亿元，同比 下降 2.6%；其中 Q2 公司实现收入 68.8 亿元，同比增长 41.2%， 环比增长 71.7%，实现归母净利润 0.85 亿元，同比增长 10.4%， 环比增长 44.2% 经营分析 风机毛利率明显修复，看好全年量利齐升：受益于"136 号文"落 地带来的风电非季节性抢装，上半年公司风电机组业务实现销量 6.3GW，同比增长 55.6%，实现收入 95.4 亿元，同比增长 47.1%， 上半年公司风机毛利率为 7.27%，同比提升 2.15pct，环比 24H2 提 升 0.66pct。展望下半年，随着国内风电行业进入常规装机旺季， 以及去年四季度以来的涨价订单陆续进入排产周期，看好公司风 机制造量利齐升趋势延续。 电站建设稳步推进，发电收入大幅增长：截至报告期末，公司累计 权益并网容量约 1.2GW，环比期初新增约 182MW；收入口径看，上 半年实现发电收入约 2.2 亿元，同比增长 31.1%；受"136 号文" 落地带来的政策不确 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company reported a revenue of 1.235 billion yuan for H1 2025, a year-on-year decrease of 17.22%, with a net profit attributable to the parent company of 242 million yuan, down 19.58% year-on-year [2] - Domestic revenue for H1 2025 was 810 million yuan, reflecting a decline of 25.79% year-on-year, primarily due to weak downstream demand [3] - The company achieved overseas revenue of 425 million yuan in H1 2025, an increase of 6.12% year-on-year, indicating robust growth in international markets [3] Summary by Sections Performance Review - In H1 2025, the company achieved total revenue of 1.235 billion yuan, down 17.22% year-on-year, and a net profit of 242 million yuan, down 19.58% year-on-year [2] - Q2 2025 saw revenue of 581 million yuan, a decrease of 27.50% year-on-year, with a net profit of 110 million yuan, down 31.07% year-on-year [2] Operational Analysis - Domestic revenue faced pressure, with a reported 810 million yuan in H1 2025, down 25.79% year-on-year, attributed to weak demand [3] - The domestic gross margin for H1 2025 was 27.80%, a decline of 2.08 percentage points year-on-year [3] - The company is optimistic about overseas growth, with a gross margin of 39.93% in H1 2025, an increase of 3.67 percentage points year-on-year [3] Future Outlook - Revenue projections for 2025 to 2027 are estimated at 2.536 billion yuan, 2.829 billion yuan, and 3.207 billion yuan respectively, with net profits expected to be 484 million yuan, 561 million yuan, and 663 million yuan [5] - The company is focusing on automation upgrades in furniture manufacturing, which is expected to enhance market share [4]

◼ 8 月 27 日晚间公司披露 25 年中报，1H25 实现营收 391.7 亿 元，同比-0.5%；实现归母净利润 59.5 亿元，同比-16.3%。2Q25 实现营收 191.4 亿元，同比-5.2%；实现归母净利润 29.3 亿元， 同比-16.5%。 ◼ 我们预计公司 2025~2027 年 分 别 实 现 归 母 净 利 润 100.8/101.5/115.2 亿元，EPS 分别为 0.20/0.20/0.23 元，对 应 PE 分别为 19 倍、19 倍和 17 倍，维持"买入"评级。 ◼ 核电站安全运营风险、核电机组检修影响电量风险、电力价格 波动风险等。 敬请参阅最后一页特别声明 1 0 500 1,000 1,500 2,000 2,500 3,000 3.00 4.00 5.00 6.00 7.00 240828 241128 250228 250531 | 公司基本情况 (人民币) | | | | | | | --- | --- | --- | --- | --- | --- | | 项目 | 2023 | 2024 | 2025E | 2026E | 2027E | | 营业收入(百 ...

业绩简评 2025 年 8 月 27 日，公司披露 25 年半年报，期内实现营收 527.7 亿元，同比+4.2%；归母净利 194.9 亿元，同比+2.3%。其中，25Q2 实现营收 158.3 亿元，同比+0.1%；归母净利 46.3 亿元，同比-7.6%。 经营分析 产品结构方面，主品牌持续优化"1+3"架构，八代普五份额稳定， 1618、39 度五粮液开瓶量&宴席场次稳定增长，浓香系列酒适应消 费趋势、中低价位酒明显放量。25H1 五粮液/其他酒分别实现营收 410.0/81.2 亿元，同比分别 +4.6%/+2.7% ， 其 中 销 量 分 别 +12.7%/+58.8% ， 吨 价 分 别 -7.2%/-35.3% ， 毛 利 率 分 别 -0.2pct/-1.5pct 至 86.5%/60.7%。 拆分渠道及区域结构：1）25H1 经销/直销收入分别为 279.2/211.9 亿元，同比 +1.2%/+8.6% ，毛利率分别 -1.0pct/+0.1pct 至 78.7%/86.8%。2）期内公司将原 27 个大区整合为三大片区，形成 "总部-区域中心-终端"的垂直管控体系。25H1 东部/南部 ...